Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $45.02, above its previous 52-week high of $45.01 with 3.7 million shares traded as of 11:05 a.m. ET. Average volume has been 6.5 million shares over the past 30 days.
Eli Lilly and has a market cap of $50.9 billion and is part of the
industry. Shares are up 7.3% year to date as of the close of trading on Monday.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has a P/E ratio of 12.1, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
TheStreet Ratings rates Eli Lilly and as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. You can view the full
52-week high stocks
or get investment ideas from our